News
Public · Published
Guardant Health Price Target Raised to $210.00/Share From $195.00 by BTIG
BTIG raised its price target on Guardant Health shares to $210.00 from $195.00 and maintained a Buy rating on the stock, according to ratings actions reported by Benzinga.
Published:
Updated:
What happened
BTIG raised its price target on Guardant Health shares to $210.00 from $195.00 and maintained a Buy rating on the stock, according to ratings actions reported by Benzinga.
Confirmed
Global impact / market context
A higher price target signals the analyst expects more upside in Guardant Health shares than before. The maintained Buy rating tells investors BTIG still sees the stock as worth owning, which can support demand for the shares.
Analyst inference
Analyst price targets are estimates of where a stock may trade, not guarantees. This upgrade of the target, with the rating unchanged, suggests BTIG's view of Guardant Health's prospects improved while its overall recommendation stayed positive.
Analyst inference
What to watch
- BTIG maintained its Buy rating on Guardant Health while raising the price target, so the rating itself did not change in this update. Confirmed
- Watch whether other analysts follow BTIG by raising their own price targets for Guardant Health, which could reinforce the positive view. Proposed
- Track Guardant Health's future revenue and cost reports, since analyst targets often depend on profit and growth trends that are not detailed here. Analyst inference
Evidence
- Original source link unavailable